Literature DB >> 31504132

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration.

G Mountzios1, J Remon2, S Novello3, N Blais4, R Califano5, T Cufer6, A M Dingemans7, S V Liu8, N Peled9, N A Pennell10, M Reck11, C Rolfo12, D Tan13, J Vansteenkiste14, H West15, B Besse16.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31504132     DOI： 10.1093/annonc/mdz295

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

Review 1.  Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?

Authors:  Diego L Kaen; Nicolas Minatta; Alessandro Russo; Umberto Malapelle; Diego de Miguel-Pérez; Christian Rolfo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50.

Authors:  Nick Freemantle; Yingxin Xu; Florence R Wilson; Patricia Guyot; Chieh-I Chen; Sam Keeping; Gerasimos Konidaris; Keith Chan; Andreas Kuznik; Kokuvi Atsou; Emily Glowienka; Jean-Francois Pouliot; Giuseppe Gullo; Petra Rietschel
Journal:  Ther Adv Med Oncol       Date:  2022-06-16       Impact factor: 5.485

3.  Tracking the tail.

Authors:  Alex Friedlaender; Stephen V Liu; Alfredo Addeo
Journal:  J Immunother Cancer       Date:  2020-09       Impact factor: 13.751
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.